AVO therapy offered sustained remission and undetectable MRD in patients with TP53 aberrations. Combination therapy with acalabrutinib, venetoclax, and obinutuzumab (AVO) is found to be highly ...

All types of birth control evaluated were associated with an increased risk of any cancer, and most types of birth control were associated with an increased risk of breast cancer. Note: This ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic ...

The variability in levels of decision regret underscores the complexity of treatment decisions and the need for individualized patient support. Decision regret was a significant concern for women ...

In 37% of cases, patients said the doctor had little time to discuss patient-identified information. US cancer patients have reported positive and negative experiences when sharing patient ...

Source: Getty Images This review discusses the effects of social isolation and loneliness on quality of life and outcomes for patients with cancer. In a 2023 systematic review focused on young ...

Median time to correct treatment significantly shorter for mpMRI-staged versus transurethral resection of bladder cancer-staged care. HealthDay News — Incorporating multiparametric magnetic ...

Outpatient management of cancer-associated PE had 30-day adverse outcome rates of 1.74% for all-cause mortality, 2.71% for major bleeding, and 1.26% for recurrent VTE. Outpatient management of ...

The consensus-driven ERAS and SSC protocols established in this study provide a standardized yet adaptable framework for perioperative management of spinal metastases. The establishment of an ...

Survey results add to evidence showing that more than half of US patients with mCSPC are still receiving androgen deprivation therapy (ADT) alone or ADT with a nonsteroidal antiandrogen.

Compared with patients with undetectable ctDNA levels in this study, patients with detectable ctDNA had an increased risk of inferior EFS at day 43. Circulating tumor DNA (ctDNA) levels appear to ...

50 percent of patients with CIN3 had histopathological complete response; 63 percent had HPV16 clearance. HealthDay News — For patients with human papillomavirus (HPV) type 16 (HPV16)-positive ...